Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kymera Therapeutics, Inc. (KYMR : NSDQ)

• Company Description    Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States. Number of Employees: 188

• Price / Volume Information    Yesterday's Closing Price: $29.11 Daily Weekly Monthly 20 Day Moving Average: 728,838 shares Shares Outstanding: 65.12 (millions) Market Capitalization: $1,895.57 (millions) Beta: 2.18 52 Week High: $53.27 52 Week Low: $19.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 21.55% 17.78% 12 Week -17.18% -11.00% Year To Date -27.64% -24.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 North Beacon Street 4th Floor - Watertown,MA 02472 USA ph: 857-285-5300 fax: - investors@kymeratx.com http://www.kymeratx.com

• General Corporate Information    Officers Nello Mainolfi - Chief Executive Officer and President Bruce Booth - Chair of the Board of Directors Bruce Jacobs - Chief Financial Officer Felix Baker - Director Jeff Albers - Director Peer Information Kymera Therapeutics, Inc. (CORR.) Kymera Therapeutics, Inc. (RSPI) Kymera Therapeutics, Inc. (CGXP) Kymera Therapeutics, Inc. (BGEN) Kymera Therapeutics, Inc. (GTBP) Kymera Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501575104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/09/25 Share - Related Items Shares Outstanding: 65.12 Most Recent Split Date: (:1) Beta: 2.18 Market Capitalization: $1,895.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.95 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/09/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.26 Price/Cash Flow: - Price / Sales: 40.27 EPS Growth vs. Year Ago Period: -252.00% vs. Previous Quarter: -7.32% Sales Growth vs. Year Ago Period: -84.56% vs. Previous Quarter: 97.65% ROE 03/31/25 - - 12/31/24 - -28.66 09/30/24 - -24.96 ROA 03/31/25 - - 12/31/24 - -24.15 09/30/24 - -20.27 Current Ratio 03/31/25 - - 12/31/24 - 7.53 09/30/24 - 8.55 Quick Ratio 03/31/25 - - 12/31/24 - 7.53 09/30/24 - 8.55 Operating Margin 03/31/25 - - 12/31/24 - -475.57 09/30/24 - -191.26 Net Margin 03/31/25 - - 12/31/24 - -475.57 09/30/24 - -191.26 Pre-Tax Margin 03/31/25 - - 12/31/24 - -475.57 09/30/24 - -191.26 Book Value 03/31/25 - - 12/31/24 - 12.90 09/30/24 - 13.79 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - - 12/31/24 - 0.27 09/30/24 - 0.19

Powered by Zacks Investment Research ©